Persistence at 24 months with denosumab among postmenopausal women with osteoporosis: results of a prospective cohort study

Vertebral Fractures After Discontinuation of Denosumab: A Post Hoc Analysis of the Randomized Placebo-Controlled FREEDOM Trial and Its Extension

(2017) Steven R Cummings et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Observations following discontinuation of long-term denosumab therapy

(2017) M. R. McClung et al.   OSTEOPOROSIS INTERNATIONAL

10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension

(2017) Henry G Bone et al.   Lancet Diabetes & Endocrinology

Two-year persistence and compliance with osteoporosis therapies among postmenopausal women in a commercially insured population in the United States

(2017) Emily Durden et al.   Archives of Osteoporosis

Factors associated with high 24-month persistence with denosumab: results of a real-world, non-interventional study of women with postmenopausal osteoporosis in Germany, Austria, Greece, and Belgium

(2017) A. Fahrleitner-Pammer et al.   Archives of Osteoporosis

Relationship Between Gastrointestinal Events and Compliance With Osteoporosis Therapy: An Administrative Claims Analysis of the US Managed Care Population

(2016) Ankita Modi et al.   CLINICAL THERAPEUTICS

GRAND-4: the German retrospective analysis of long-term persistence in women with osteoporosis treated with bisphosphonates or denosumab

(2016) P. Hadji et al.   OSTEOPOROSIS INTERNATIONAL

Association between teriparatide treatment persistence and adherence, and fracture incidence in Taiwan: analysis using the National Health Insurance Research Database

(2016) D.-C. Chan et al.   OSTEOPOROSIS INTERNATIONAL

Persistence with denosumab and zoledronic acid among older women: a population-based cohort study

(2016) Éric Tremblay et al.   Archives of Osteoporosis

Persistence, adherence, and medication-taking behavior in women with postmenopausal osteoporosis receiving denosumab in routine practice in Germany, Austria, Greece, and Belgium: 12-month results from a European non-interventional study

(2015) P. Hadji et al.   OSTEOPOROSIS INTERNATIONAL

Persistence at 12 months with denosumab in postmenopausal women with osteoporosis: interim results from a prospective observational study

(2014) S. L. Silverman et al.   OSTEOPOROSIS INTERNATIONAL

Long-term persistence and switching patterns among women using osteoporosis therapies: 24- and 36-month results from POSSIBLE US™

(2014) S. W. Wade et al.   OSTEOPOROSIS INTERNATIONAL

Treatment persistence and changes in fracture risk, back pain, and quality of life amongst patients treated with teriparatide in routine clinical care in France: Results from the European Forsteo Observational Study

(2013) Gerald Rajzbaum et al.   JOINT BONE SPINE

Persistence with osteoporosis medication among newly-treated osteoporotic patients

(2013) Job F. M. van Boven et al.   JOURNAL OF BONE AND MINERAL METABOLISM

Atypical Subtrochanteric and Diaphyseal Femoral Fractures: Second Report of a Task Force of the American Society for Bone and Mineral Research

(2013) Elizabeth Shane et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Persistence and compliance of medications used in the treatment of osteoporosis – analysis using a large scale, representative, longitudinal German database

(2012) Volker Ziller et al.   INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS

Long-term impact of adherence to oral bisphosphonates on osteoporotic fracture incidence

(2011) John S Sampalis et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Persistence with intravenous zoledronate in elderly patients with osteoporosis

(2011) Y.-K. Lee et al.   OSTEOPOROSIS INTERNATIONAL

Bisphosphonate prescribing, persistence and cumulative exposure in Ontario, Canada

(2011) A. M. Burden et al.   OSTEOPOROSIS INTERNATIONAL

Final results of the DAPS (Denosumab Adherence Preference Satisfaction) study: a 24-month, randomized, crossover comparison with alendronate in postmenopausal women

(2011) N. Freemantle et al.   OSTEOPOROSIS INTERNATIONAL

Sclerostin Stimulates Osteocyte Support of Osteoclast Activity by a RANKL-Dependent Pathway

(2011) Asiri R. Wijenayaka et al.   PLoS One

A Meta-Analysis of Osteoporotic Fracture Risk with Medication Nonadherence

(2011) Susan Ross et al.   VALUE IN HEALTH

Adherence and persistence in patients with severe osteoporosis treated with teriparatide

(2010) V. Ziller et al.   CURRENT MEDICAL RESEARCH AND OPINION

Adherence, preference, and satisfaction of postmenopausal women taking denosumab or alendronate

(2010) D. L. Kendler et al.   OSTEOPOROSIS INTERNATIONAL

Weekly versus monthly drug regimens: 1-year compliance and persistence with bisphosphonate therapy

(2009) Deborah T. Gold et al.   CURRENT MEDICAL RESEARCH AND OPINION

Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy

(2009) David L Kendler et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis

(2009) Steven R. Cummings et al.   NEW ENGLAND JOURNAL OF MEDICINE

Adherence to monthly and weekly oral bisphosphonates in women with osteoporosis

(2009) F.-E. Cotté et al.   OSTEOPOROSIS INTERNATIONAL

Comparison of the Effect of Denosumab and Alendronate on BMD and Biochemical Markers of Bone Turnover in Postmenopausal Women With Low Bone Mass: A Randomized, Blinded, Phase 3 Trial*

(2008) Jacques P Brown et al.   JOURNAL OF BONE AND MINERAL RESEARCH